Group 1: Mechanical Equipment Industry - The report highlights the strong demand for both aviation engines and gas turbines, driven by the recovery of the aviation market and new power demands from AIDC, leading to a supply-demand imbalance in the industry [2][8] - Major players in the aviation engine market include GE, PW, and R&R, while gas turbine leaders are Mitsubishi Heavy Industries, Siemens Energy, and GE Vernova, indicating a competitive landscape dominated by foreign companies [2][11] - The backlog of orders for commercial aircraft remains historically high, with Boeing and Airbus having a combined backlog of 15,241 aircraft as of July 2025, which is expected to sustain high demand for the aviation engine sector [9] Group 2: Non-Banking Financial Sector - CITIC Financial Assets has shifted its focus to non-performing asset management and has disposed of most of its financial subsidiaries, allowing it to concentrate on core operations [4][13] - The company is actively investing in high-quality listed companies, holding stakes in major banks like Bank of China and CITIC Limited, which are expected to provide stable returns [4][15] - The report projects that the long-term equity investment strategy will effectively smooth out economic cycle fluctuations for CITIC Financial Assets [4][13] Group 3: Communication Industry - Runze Technology is positioned as a leading IDC provider with strong resource endowments and financing advantages through REITs, which are expected to drive high growth [5][16] - The company is set to benefit from the upward trend in IDC demand, particularly in first-tier cities and surrounding areas, as the industry shifts from cloud computing to AI-driven needs [5][16] - EBITDA projections for Runze Technology are expected to grow significantly from 3.689 billion yuan in 2025 to 6.388 billion yuan by 2027 [5][16] Group 4: Pharmaceutical and Biological Sector - Tianshili, a leading traditional Chinese medicine company, is expected to see EPS growth from 0.79 yuan in 2025 to 0.98 yuan by 2027, supported by strong R&D capabilities and a robust marketing system [6][21] - The company has accelerated its R&D pipeline under the influence of China Resources, with a focus on cardiovascular, neurological, and digestive products [6][20] - The report indicates that Tianshili's revenue for the first half of 2025 was 4.288 billion yuan, with a net profit of 775 million yuan, reflecting a stable performance despite market challenges [19][20]

Investment Rating - The report maintains a "Buy" rating for the company, indicating a potential upside of over 15% relative to the benchmark index [4]. Core Insights - The company achieved significant growth in the first half of 2025, with revenue reaching 1.46 billion RMB, a year-on-year increase of 28.2%, and net profit of 170 million RMB, up 35.5% [1]. - The "internal growth + external acquisition" strategy has proven effective, particularly with the acquisition of the brand Nairui, which contributed 277 million RMB in revenue and improved its net profit margin from 6.5% to 10.4% [3]. - The company reported a gross margin of 49.3%, an increase of 2.3 percentage points year-on-year, and a net profit margin of 11.70%, up 0.62 percentage points [3]. Revenue Breakdown - The revenue from beauty and wellness services was 810 million RMB, a 29.6% increase, accounting for 55.2% of total revenue. Direct store income was 740 million RMB, up 31.0% [2]. - Medical beauty services generated 500 million RMB, a 13.0% increase, representing 34.2% of total revenue [2]. - The revenue from sub-health medical services doubled to 150 million RMB, a 107.8% increase, making up 10.6% of total revenue [2]. Membership Growth - The company reported a 47.8% increase in direct store customer traffic, reaching 920,000 visits, and active membership grew by 46.5% to 120,000 [4]. - Approximately 20% of beauty and wellness service members upgraded to medical beauty or sub-health services, enhancing the penetration of high-value business [4]. Financial Forecast - The company is projected to achieve net profits of 330 million RMB, 380 million RMB, and 430 million RMB for 2025, 2026, and 2027, respectively, with growth rates of 43.9%, 17.0%, and 12.2% [4][5]. - The current stock price corresponds to a price-to-earnings ratio (P/E) of 23X for 2025, 20X for 2026, and 18X for 2027 [4][5].

Core Viewpoint - Meili Tianyuan Medical Health Industry Co., Ltd. reported a strong performance for the first half of 2025, with revenue of 1.46 billion yuan, a year-on-year increase of 28.2%, and a net profit of 170 million yuan, up 35.5% [1] Financial Performance - Revenue for the first half of 2025 reached 1.46 billion yuan, reflecting a 28.2% year-on-year growth - Net profit was 170 million yuan, representing a 35.5% increase compared to the previous year - Gross margin improved to 49.3%, up 2.3 percentage points year-on-year - Cash and cash-equivalent assets amounted to 2 billion yuan, a 27.5% increase year-on-year - Operating cash flow for the first half was 410 million yuan, showing an 84.4% year-on-year growth [1] Business Segments - The company operates in three main business segments: Beauty and Health Services, Medical Beauty Services, and Sub-health Medical Services - Beauty and Health Services generated 810 million yuan in revenue, a 29.6% increase, with a gross margin of 42.1% [2] - Medical Beauty Services saw revenue rise to 500 million yuan, a 13.0% increase, with a gross margin of 56.9% [2] - Sub-health Medical Services experienced explosive growth, with revenue of 150 million yuan, up 107.8%, and a gross margin of 63.1% [2] Market Trends - Consumer demand is shifting towards emotional connections and spiritual resonance, with emotional value significantly influencing the younger generation's purchasing decisions - The emotional economy market in China is expected to reach 2.3 trillion yuan by 2025, indicating a potential for explosive growth [1] Store Network and Expansion - As of June 30, the company had a total of 522 stores, including 273 direct-operated and 279 franchised or managed stores - The company has a strong presence in first-tier cities, with 157 direct-operated stores in Beijing, Shanghai, Guangzhou, and Shenzhen, contributing over 60% of total revenue [3] Shareholder Return Plan - The company announced a shareholder return plan, committing to distribute at least 50% of annual net profit as dividends over the next three fiscal years, barring special circumstances - The first dividend payment of 0.52 HKD per share is scheduled for distribution by September 26 [3] Acquisition Strategy - The company has pursued rapid expansion through acquisitions, including a 70% stake in the second-largest beauty brand, Nairui'er, for 350 million yuan - Nairui'er generated revenue of 277 million yuan in the first half of 2025, with an adjusted net profit margin increasing from 6.5% to 10.4% post-acquisition [4][5] - The company aims to replicate the successful integration of Nairui'er to explore further industry consolidation opportunities [5]

Core Viewpoint - The company maintains its net profit forecast for 2025-2026, with the current stock price corresponding to a P/E ratio of 20x and 18x for the non-deductible net profit for 2025-2026, indicating a 29% upside potential to the target price of HKD 37 [1] Financial Performance - The company expects a revenue of no less than HKD 1.45 billion for 1H25, representing a year-on-year increase of at least 27%, and a net profit of no less than HKD 170 million, reflecting a growth of at least 35%. The adjusted net profit is projected to be no less than HKD 175 million, with a growth of at least 33% [2] - The performance exceeds expectations due to revenue structure optimization leading to improved gross margins, scale effects, and operational efficiency enhancing net profit margins [2] Revenue Growth Drivers - The company anticipates a revenue growth of at least 27% for 1H25, driven by both internal and external factors. Internally, customer traffic is expected to grow by over 10%. Externally, the acquisition of Naieryer is projected to contribute approximately HKD 276 million in revenue, with single-store revenue increasing by over 10% compared to pre-acquisition levels [3] - By business segment, the company expects a net consumption growth of about 30% in lifestyle beauty and health, over 10% in medical beauty, and over 100% in sub-health medical services, with internal net consumption also increasing by over 50% [3] Margin Improvement - The company projects a gross margin increase of 0.8 percentage points and a net margin increase of 0.6 percentage points to 11.7% for 1H25. The net profit margins for internal business and Naieryer are expected to increase by 1 percentage point and 3 percentage points, respectively [4] - The improvement in profitability is attributed to a higher proportion of high-margin business revenue, reduced procurement costs from scale purchasing and deeper collaborations, as well as cost reductions in rent and operational efficiencies driven by digitalization [4] Growth Outlook - The company is optimistic about its growth prospects driven by a dual engine of internal and external growth. Internally, it aims to enhance single-store operational efficiency and increase the penetration of value-added services through digital marketing [5] - Externally, the company is actively exploring merger and acquisition opportunities to enhance market share, with expectations of continued expansion of membership assets and nationwide layout [5]

Core Viewpoint - The company is expected to achieve a revenue of no less than 1.45 billion yuan in 25H1, representing a year-on-year increase of 27%, and an adjusted net profit of no less than 175 million yuan, reflecting a year-on-year growth of 33% [1] Group 1: Performance and Growth - The company maintains strong performance growth despite a complex industry backdrop, showcasing resilience as a market leader [1] - The core business segments, beauty and health, show stable internal growth and external market share expansion, with a year-on-year increase in internal customer flow of 10% in 25H1 [1] - The health management segment is experiencing robust growth driven by functional medicine and women's health services [1] Group 2: Business Model and Strategy - The company employs a "Double Beauty + Double Health" model, providing customers with both emotional and functional value throughout their lifecycle, indicating significant potential for customer base expansion and value enhancement [1] - The board attributes performance improvement to the refinement of the "Double Beauty + Double Health" business model, which has increased the proportion of high-margin business revenue, thereby optimizing the revenue structure and improving gross margin levels [1] Group 3: Shareholder Value and Market Confidence - The company has executed a share buyback, purchasing 60,500 shares for a total transaction amount of 1.762 million HKD, with an average transaction price of approximately 29.12 HKD, reflecting management's confidence in the company's long-term development [1] - The share buyback is expected to enhance the company's market value and shareholder return capabilities [1] Group 4: Profit Forecast and Valuation - The company's net profit forecasts for 25-27 are adjusted to 320 million, 369 million, and 420 million yuan respectively, with a compound annual growth rate (CAGR) of 22% [2] - The target price for the company is set at 37.36 HKD, based on a 25x price-to-earnings ratio for 25, reflecting its status as a leading brand in beauty and health [2]

Summary of the Conference Call for Meili Tianyuan Company Overview - **Company**: Meili Tianyuan - **Industry**: Health and Beauty, specifically focusing on wellness, beauty care, and medical aesthetics Key Points and Arguments Financial Performance - In the first half of 2025, Meili Tianyuan's overall operations met expectations, with both equity capital and net consumer traffic increasing by approximately 20% [2][5] - The sub-sector of sub-health showed outstanding performance with a year-on-year growth of 50% [2][5] - The beauty and health business grew by 20%, while the medical aesthetics business grew by 10%, primarily driven by offline customer traffic [2][5] - The company is confident in achieving its annual revenue target of 2 billion and profit target of 320 million [2][6][7] Business Strategy - The company will not adjust its annual performance expectations and anticipates a 30%-40% growth in the sub-health business [2][8] - The store opening strategy is "one city, one store," focusing on beauty and health memberships, with stable store numbers but increased single-store efficiency through upgrades and expansions [2][9] - Meili Tianyuan aims to enhance its net profit margin by 0.5 percentage points through supply chain optimization, digitalization, and backend cost reduction [2][11] Profitability Metrics - The gross margin for the beauty and health business is approximately 30%, with an operating profit margin of 5%-10% [2][11] - The medical aesthetics business has a gross margin exceeding 50% and an operating profit margin close to 40% [2][11] - The sub-health business has recently surpassed a gross margin of 50%, with potential to align with medical aesthetics in the future [2][11] Market Position and Growth - Currently, the market share is about 0.04%, and the company plans to increase this through organic growth, store openings, membership expansion, and mergers and acquisitions [3][14] - Meili Tianyuan has become a leader in the chain industry, having acquired a top-five player, Nairui, in 2024 [13][14] Shareholder Changes - A significant shareholder, CPE, has exited, transferring shares to other core institutional shareholders, which has improved liquidity and resolved previous low trading volume issues [4][12] Future Plans - The company is optimistic about its long-term growth and plans to continue integrating and optimizing Nairui's operations [15][21] - Future acquisitions will focus on high-quality suppliers and compatible brands that align with customer profiles [21][23] Marketing and Customer Engagement - Meili Tianyuan has three major promotional events planned for the year, with a focus on overall growth rather than individual events [27] - Customer traffic has increased across all segments, with new product launches contributing to revenue growth [28] Brand Positioning - The company is viewed as an attractive growth-oriented chain in the market, with stable growth reinforcing brand strength [29] Additional Important Information - The company is currently meeting the turnover rate requirements for the Hong Kong Stock Connect and is working towards meeting market capitalization coverage requirements [12] - The average spending per visit in the medical aesthetics sector is around 30,000 yuan, with customers visiting three to four times a year [25]